[97] observed that liraglutide use was an independent negative predictor of LV mass index, suggesting liraglutide might prevent the progression of post-MI LV remodeling
Scott Kahan, an obesity medicine specialist in Washington, D.C., said its very important that patients continue to get enough calories, even though the medication will make them feel less hungry
[5] Small-molecule NNMT inhibitors were then developed to reproduce that effect pharmacologically: in cultured adipocytes, 5-Amino-1MQ-type inhibitors lowered 1-methylnicotinamide, raised intracellular NAD and SAM, and suppressed lipogenesis
Additional beneficial cardiometabolic effects may include the promotion of ketogenesis and possibly anti-inflammatory effects [48]
Durability of healing improvements (long-term follow-up data)
Journal of the American Academy of Dermatology , 70(3), 489498.